ClinicalRM receives BARDA contract to support MCM studies
With the contract award, ClinicalRM will become part of a clinical studies network planned by BARDA to support the development of diagnostics, drugs and vaccines meant to protect individuals involved in public health emergencies. The network will provide clinical services to support Phase I through IV clinical trials or trials during a public health emergency.
ClinicalRM is one of five companies to receive the award. The contract is a two-year contract with three one-year options BARDA may exercise. If all options are exercised, the contract will be worth up to $100 million.
"We look forward to working with BARDA to evaluate new treatments for medical conditions that could have devastating impacts on many people," David Hoover, the program director for ClinicalRM, said. "New treatments are vitally important for improved management of infectious diseases and exposures to a broad range of toxic agents."
The network will support the evaluation of chemical, biological, radiological, nuclear, pandemic influenza and emerging infectious disease medical countermeasures. ClinicalRM specialists in preclinical and clinical research and product development for biologics, drugs and devices.
"ClinicalRM is proud to engage in this critical work with BARDA," Victoria Tifft, the CEO of ClinicalRM, said. "The award of this contract allows us to continue to build strong and meaningful partnerships with the government, industry, and academia to combat a variety of potential national threats."